Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
May 12, 2023
Ryan Allway May 12th, 2023 News, Top News, Top Story News provided by Clearmind Medicine, May 12, 2023 IMCA medical center’s ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)... Read more
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
March 16, 2023
Ryan Allway March 16th, 2023 Psychedelics, Top News Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel / Vancouver, Canada, March 16, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and... Read more
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3
January 28, 2022
Ryan Allway January 28th, 2022 Psychedelics A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or... Read more
Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
October 7, 2021
Ryan Allway October 7th, 2021 Psychedelics The Regulatory affairs and CRO will oversee the Company’s efforts to secure an IND review of MEAI as a potential treatment for Alcohol Use Disorder and binge drinking Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0),... Read more
